Robert Petit - 22 Jan 2026 Form 4 Insider Report for OS Therapies Inc (OSTX)

Reporting relationship: Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.
Issuer ticker: OSTX
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 16:41:51 UTC
Prior SEC filing: 19 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Petit

Key filing fact

Robert Petit filed Form 4 for OS Therapies Inc (OSTX) on 13 Feb 2026.

Key facts

This page summarizes Robert Petit's Form 4 filing for OS Therapies Inc (OSTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Feb 2026, 16:41.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001576077 Primary reporting owner

PETIT ROBERT

Relationship: Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.
Address: C/O OS THERAPIES INCORPORATED, 115 PULLMAN CROSSING ROAD, SUITE 103, GRASONVILLE
Signature: /s/ Robert Petit
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OSTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 200,000
Date: 22 Jan 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OSTX transaction Derivative

Stock options (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 22 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $1.34
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On January 22, 2026, the reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

SEC remarks

Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.